Neither Amgen nor Johnson & Johnson could possibly have imagined three years ago that they would be registering oncologists in a program intended to curtail use of two blockbuster products, the erythropoiesis stimulating agents Aranesp (darbepoetin) and Procrit (epoetin).
But, after a long and difficult period of safety scrutiny, that is exactly what the companies are doing, thanks to a Risk Evaluation & Mitigation Strategy announced February 16.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?